Cristina Truica, MD - Penn State Cancer Institute
Researcher Profile
Cristina Truica, MD
Associate Professor, Department of Medicine
Director of Breast Medical Oncology, Division of Hematology and Oncology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Director of Breast Medical Oncology, Division of Hematology and Oncology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Scientific Program:Next-Generation Therapies
Disease Teams:
Cancer Institute, Breast Cancer Team
Clinical Trials
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
CCTG MA.39:Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score (OFSET)
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase nhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No evidence of Disease
S1501, Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence -A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers
A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study) (HCRN-BRE20-468)
EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
Recent Publications
2024
Derbes, R, Hakun, J, Elbich, D, Master, L, Berenbaum, S, Huang, X, Buxton, OM, Chang, AM, Truica, CI & Sturgeon, KM 2024, 'Design and methods of the mobile assessment of cognition, environment, and sleep (MACES) feasibility study in newly diagnosed breast cancer patients', Scientific reports, vol. 14, no. 1, 8338. https://doi.org/10.1038/s41598-024-58724-1
2023
Bluethmann, SM, Flores, E, Grotte, M, Heitzenrater, J, Truica, CI, Olsen, NJ, Sciamanna, C & Schmitz, KH 2023, 'Adapting an Evidence-Based Exercise and Education Program for Older Breast Cancer Survivors for the REJOIN Trial', Journal of Aging and Physical Activity, vol. 31, no. 1, pp. 59-67. https://doi.org/10.1123/japa.2022-0013
Gordon, BR, Qiu, L, Doerksen, SE, Kanski, B, Lorenzo, A, Truica, CI, Vasekar, M, Wang, M, Winkels, RM, Abdullah, S & Schmitz, KH 2023, 'Addressing metastatic individuals everyday: Rationale and design of the nurse AMIE for Amazon Echo Show trial among metastatic breast cancer patients', Contemporary Clinical Trials Communications, vol. 32, 101058. https://doi.org/10.1016/j.conctc.2023.101058
Schmitz, KH, Kanski, B, Gordon, B, Caru, M, Vasakar, M, Truica, CI, Wang, M, Doerksen, S, Lorenzo, A, Winkels, R, Qiu, L & Abdullah, S 2023, 'Technology-based supportive care for metastatic breast cancer patients', Supportive Care in Cancer, vol. 31, no. 7, 401. https://doi.org/10.1007/s00520-023-07884-3
Caru, M, Abdullah, S, Qiu, L, Kanski, B, Gordon, B, Truica, CI, Vasakar, M, Doerksen, S & Schmitz, KH 2023, 'Women with metastatic breast cancer don't just follow step-count trends, they exceed them: an exploratory study', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 265-270. https://doi.org/10.1007/s10549-023-06980-6
2022
Teslenko, I, Trudeau, J, Luo, S, Watson, CJW, Chen, G, Truica, CI & Lazarus, P 2022, 'Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated with Exemestane', Journal of Pharmacology and Experimental Therapeutics, vol. 382, no. 3, pp. 327-334. https://doi.org/10.1124/jpet.122.001232
2021
Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, JJ & Joshi, M 2022, 'Group-led creative writing and behavioural health in cancer: A randomised clinical trial', BMJ Supportive and Palliative Care, vol. 12, no. 1, pp. 91-98. https://doi.org/10.1136/bmjspcare-2020-002463
Bluethmann, SM, Truica, C, Klepin, HD, Olsen, N, Sciamanna, C, Chinchilli, VM & Schmitz, KH 2021, 'Study design and methods for the using exercise to relieve joint pain and improve AI adherence in older breast cancer survivors (REJOIN) trial', Journal of Geriatric Oncology, vol. 12, no. 7, pp. 1146-1153. https://doi.org/10.1016/j.jgo.2021.05.011
Schmitz, KH, Schleicher, E, Doerksen, S, Truica, C, Cream, L, Kass, R, Farnan, M, Suess, R, Gordon, B, Zucker, D & Hayes, M 2021, 'Testing the acceptability and feasibility of a tablet-based supportive cancer platform for patients with metastatic breast cancer', Journal of Cancer Survivorship, vol. 15, no. 3, pp. 410-413. https://doi.org/10.1007/s11764-021-01021-x